DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA...

DTx Pharma Completes $100M Series B Financing to Advance its FALCON™ Platform and Pipeline of RNA Therapeutics


"Proceeds will enable further platform development and accelerate the path toward clinical development


Matthew Hammond, Ph.D., Principal at RA Capital Management, and Dan Becker, M.D., Ph.D., Partner at Access Biotechnology, will join DTx Pharma's board of directors..."


030221 DTx Pharma Completes $100M Series
.
Download • 68KB


Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC